Dipharma Francis3A41The Dipharma Group is a global CDMO and a leading manufacturer of APIs, New Chemical Entities (NCE), and advanced Intermediates for Generic and Contract Manufacturing markets, offering about 40 APIs with DMFs registered worldwide. Thanks to a workforce of about 600 skilled and highly committed employees, supported by four state-of-the-art CGMP facilities, located in the U.S.A. and Italy, plus commercial sales offices in Italy, the U.S.A. and China, Dipharma is strategically positioned to meet the dynamic needs of the pharmaceutical industry. Our fully-equipped Research and Development Centers, supported by the internal Intellectual Property department, drive innovation by developing cutting-edge chemical processes and crystalline forms tailored to meet the unique requirements of our customers. Since 1970, Dipharma has managed to achieve a positive unbroken record of inspections by the major Regulatory Agencies and the CGMP manufacturing sites are equipped to supply quantities from laboratory to industrial scale, covering the entire lifecycle of a pharmaceutical substance. Dipharma's core technologies are: High-pressure hydrogenation, Nitration, Nitroesterification, Azide chemistry, Borane reductions, Cross-coupling reactions, Curtius reaction, Dissolving metal reduction, Enzymatic chemistry, Epichlorohydrin chemistry, Hoffman reaction, Hydrogen peroxide oxidations, Carbohydrate chemistry, Enantioselective reactions, Use of nitroalkanes (Henry reaction), Wolff-Kishner reduction. The Dipharma Group has the right size and variety of scale-up capabilities to act as a global player and manage processes efficiently while offering flexibility and agility to promptly solve any challenge. Experience you can trust
